在生命第一年每日全身使用润肤剂预防高危儿童特应性湿疹的有效性和成本效果(BEEP试验):随机对照试验方案
BEEP试验是一项在英格兰社区、基层和二级医疗招募至高1400名有特应性湿疹(AE)高危因素的足月婴儿的实用型两臂随机对照多中心试验方案。家庭按1:1随机接受一般婴儿护肤指导或一般护肤指导加润肤剂并建议每日全身使用至1岁,主要结局为24月龄时盲法评估的AE。试验将验证每日润肤剂增强皮肤屏障能否预防高危婴儿发生AE。
要点
- BEEP试验拟招募至高1400名有AE、哮喘或过敏性鼻炎一级亲属的足月婴儿。
- 干预组在一般护肤指导外每日全身使用润肤剂至1岁,家庭对分组不设盲。
- 主要结局为24月龄时按英国工作组特应性湿疹诊断标准盲法评估的AE。
核心结论
- 该试验将证明生命第一年每日使用润肤剂增强皮肤屏障能否预防高危婴儿发生AE。
- 若有效,这一简单且廉价的干预有望通过预防AE及可能相关的其他过敏性疾病为全球医疗提供者节省大量成本。
研究设计与样本
- 实用型、两臂、随机对照、多中心试验方案。
- 计划通过英格兰社区、基层和二级医疗招募至高1400名AE高危足月婴儿。
- 参与家庭按1:1随机接受一般婴儿护肤指导或一般护肤指导加润肤剂并建议每日使用至1岁。
- 家庭对治疗分配不设盲。
主要发现
- 主要结局为24月龄时使用英国工作组特应性湿疹诊断标准盲法评估的AE。
- 次要结局包括其他AE定义、AE发病时间、AE严重度(EASI和POEM)、其他过敏性疾病(食物过敏、哮喘、花粉症)、过敏致敏、生活质量、成本效果和润肤剂安全性。
- 计划按丝聚蛋白基因型和一级亲属AE及其他过敏性疾病数量进行主要结局亚组分析。
- 家庭将在3、6、12和18月龄接受在线和邮寄问卷随访,24月龄面对面访视,长期随访至60月龄通过年度问卷进行。
关键数值与推荐
- 主要结局采用英国工作组特应性湿疹诊断标准在24月龄盲法评估。
- AE严重度采用EASI和POEM评估。
- 随机比例为1:1。
- 干预为一般护肤指导加润肤剂并建议每日全身使用至1岁。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atopic eczema (AE) is a common skin problem that impairs quality of life and is associated with the development of other atopic diseases including asthma, food allergy and allergic rhinitis. AE treatment is a significant cost burden for health care providers. The purpose of the trial is to investigate whether daily application of emollients for the first year of life can prevent AE developing in high-risk infants (first-degree relative with asthma, AE or allergic rhinitis). METHODS: This is a protocol for a pragmatic, two-arm, randomised controlled, multicentre trial. Up to 1400 term infants at high risk of developing AE will be recruited through the community, primary and secondary care in England. Participating families will be randomised in a 1:1 ratio to receive general infant skin-care advice, or general skin-care advice plus emollients with advice to apply daily to the infant for the first year of life. Families will not be blinded to treatment allocation. The primary outcome will be a blinded assessment of AE at 24 months of age using the UK Working Party Diagnostic Criteria for Atopic Eczema. Secondary outcomes are other definitions of AE, time to AE onset, severity of AE (EASI and POEM), presence of other allergic diseases including food allergy, asthma and hay fever, allergic sensitisation, quality of life, cost-effectiveness and safety of the emollients. Subgroup analyses are planned for the primary outcome according to filaggrin genotype and the number of first-degree relatives with AE and other atopic diseases. Families will be followed up by online and postal questionnaire at 3, 6, 12 and 18 months with a face-to-face visit at 24 months. Long-term follow-up until 60 months will be via annual questionnaires. DISCUSSION: This trial will demonstrate whether skin-barrier enhancement through daily emollient for the first year of life can prevent AE from developing in high-risk infants. If effective, this simple and cheap intervention has the potential to result in significant cost savings for health care providers throughout the world by preventing AE and possibly other associated allergic diseases. TRIAL REGISTRATION: ISRCTN registry; ID: ISRCTN21528841 . Registered on 25 July 2014.
引用
- Chalmers JR, Haines RH, Mitchell EJ, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial. Trials. 2017. PMID: 28732519. doi:10.1186/s13063-017-2031-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。